- Software giant bolsters sales, marketing and R&D efforts -
SAS Institute, the leader in business intelligence, has strengthened its focus on the pharmaceutical and biotechnology industries. It has absorbed iBiomatics, a wholly owned subsidiary providing innovative technology and strong domain experience in biomedical informatics. As part of this reorganisation, all iBiomatics products, which include regulatory-compliant Web-based solutions for drug discovery, development and marketing, are being rebranded and marketed as SAS products. Many former iBiomatics employees are joining SAS, adding to the market expertise of the company, which will benefit SAS customers. SAS will sell and support the iBiomatics solutions, which will be tightly integrated into SAS' industry-leading solutions. Current iBiomatics customers will receive product support from SAS.
SAS is the dominant solutions provider to the pharmaceutical and biotechnology industries. Companies use SAS to prove the safety and efficacy of drugs under development and to deliver electronic submissions to the U.S. Food and Drug Administration. This market is expanding with recent scientific advances, including the mapping of the human genome, which creates more data than ever before.
"The amount of data generated and collected by pharmaceutical companies is threatening to overwhelm traditional R&D systems," said Steve Shaha, CEO of the Institute for Integrated Outcomes, a technology analyst firm that specialises on the pharmaceutical industry. "Most companies have outgrown their existing systems already and are beyond struggling. They need a way to warehouse, manage and analyse discovery and clinical data more efficiently and effectively, or they will not be able to grow profitably and aggressively. A single vendor that provides solutions for these vital tasks would benefit the industry."
According to SAS Senior Vice President of Worldwide Marketing Jim Davis, SAS is responding to challenges faced by the industry. "We made this move to support our customers better," he said. "Pharmaceutical and biotechnology companies need to share information more easily within their own organisations and between partners. They're looking for a single-source provider to deliver this intelligence in unified, regulatory-compliant solutions. That provider is SAS."
SAS will build on the initiatives provided by iBiomatics. "iBiomatics designed solutions to satisfy critical business issues faced by pharmaceutical and biotechnology companies," said Keith Collins, chief technology officer, SAS. "We will draw on the deep resources of SAS and deliver targeted, innovative solutions that will help these companies gain market approval and market share for their products faster than ever before."
With the added pharmaceutical domain expertise, SAS will enhance existing solution offerings, such as marketing automation and business performance measurement, for pharmaceutical and biotechnology companies.
SAS provides software and services that enable customers to transform data from all areas of their business into intelligence. SAS solutions help organisations make better, more informed decisions and maximise customer, supplier, and organisational relationships. Solutions from SAS, the world's largest privately held software company, are used at more than 37,000 business, government and university sites around the world. Customers include 98 of the Fortune 100 and 90 percent of Fortune 500 companies. For 25 years, SAS has been giving our customers The Power to Know(tm).
For more information, visit http://www.sas.com
For further information, please contact the SAS press office on: tel:+44 (0)20 7544 3202
fax: +44 (0)20 7240 1910 or firstname.lastname@example.org
Please visit SAS' Web site: http://www.sas.com/uk
This press release was distributed by ResponseSource Press Release Wire on behalf of Golin in the following categories: Consumer Technology, Personal Finance, Business & Finance, Computing & Telecoms, for more information visit https://pressreleasewire.responsesource.com/about.